Lv11
20 积分 2026-03-31 加入
Abstract PD13-08: First-in-human safety and activity of ARV-471, a novel PROTAC® estrogen receptor degrader, in ER+/HER2- locally advanced or metastatic breast cancer
3个月前
已完结
Abstract P4-04-31: A phase Ib/II study of PARPi Mefuparib Hydrochloride (CVL218) in combination with PD-1 inhibitor plus chemotherapy in metastatic or recurrent triple-negative breast cancer (TNBC)
6个月前
已关闭
DHX9 inhibition enhances paclitaxel sensitivity by inducing mitotic failure in ovarian and endometrial cancers
7个月前
已完结
皖公网安备34019202002308
